Panteris Vasilios, Perdiou Anna, Tsirimpis Vasilios, Karamanolis Demetrios-Georgios
Department of Gastroenterology, "Tzaneio" General Hospital, Piraeus, Greece.
World J Gastroenterol. 2006 Oct 14;12(38):6235-8. doi: 10.3748/wjg.v12.i38.6235.
Infliximab is a potent anti-TNF antibody, which is used with great success in Crohn's disease patients. Since its release in clinical practice, several adverse reactions have been observed. The interest in possible consequences of its administration is still high because of the recent introduction of the drug for the long-term maintenance therapy of refractory luminal and fistulizing Crohn's disease. We present a case of acute coronary syndrome (non-STEMI) in a patient with corticoid resistant Crohn's disease after his first dose of infliximab. By reviewing the scant articles that exist in the literature on this topic we made an effort to delineate the possible mechanisms of this phenomenon.
英夫利昔单抗是一种强效抗TNF抗体,在克罗恩病患者中使用取得了巨大成功。自其在临床实践中应用以来,已观察到多种不良反应。由于该药物最近被用于难治性肠腔型和瘘管型克罗恩病的长期维持治疗,人们对其使用可能产生的后果仍高度关注。我们报告一例皮质类固醇抵抗的克罗恩病患者在首次注射英夫利昔单抗后发生急性冠状动脉综合征(非ST段抬高型心肌梗死)的病例。通过查阅文献中关于该主题的少量文章,我们努力阐明了这一现象可能的机制。